Robert Habib

Robert Habib is a biotechnology entrepreneur and CEO at MiNA Therapeutics, where he is pioneering a new class of RNA medicines. He studied A-Levels in Chemistry, History, and Mathematics at St Paul's School, then went on to earn a Bachelor of Science in Economics and Politics with 1st Class honors from the University of Bristol. Habib later received an MBA in General Management from Columbia Business School.

Before joining MiNA Therapeutics, Habib gained valuable experience in business development and finance. He worked as a Summer Associate at Stirling Square Capital Partners, an Analyst in UK Mergers and Acquisitions at Deutsche Bank, and as a Summer Analyst in both UK Mergers and Acquisitions and Continental Europe Corporate Finance at Deutsche Bank. He also served as Business Development Executive at EMcision Ltd.

Habib is an expert in biotechnology, RNA medicine, business development, and finance. He has a keen interest in advancing the development of innovative new therapies to improve patient outcomes.